Clinical Research Directory
Browse clinical research sites, groups, and studies.
Istradefylline for Parkinson Disease With Cognitive Impairment
Sponsor: Virginia Commonwealth University
Summary
The purpose of this research study is to determine whether istradefylline improves cognition in individuals with Parkinson disease with cognitive impairment.
Official title: Istradefylline for Parkinson Disease Cognitive Impairment
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2022-07-18
Completion Date
2025-06-09
Last Updated
2026-09-23
Healthy Volunteers
No
Conditions
Interventions
Istradefylline medication
2 weeks on istradefylline 20mg daily, 2 weeks on istradefylline 40mg with the ability to adjust other antiparkinsonian medications, and 22 weeks on istradefylline 40mg and stable antiparkinsonian medications
Locations (1)
Virginia Commonwealth University
Richmond, Virginia, United States